



Organ-On-Chip Technology: The Future of Feto-Maternal Interface Research?

Lauren Richardson^{1,2,3}, Sungjin Kim^{2,3}, Ramkumar Menon^{1*} and Arum Han^{2,3*}

¹ Division of Maternal-Fetal Medicine and Perinatal Research, Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, TX, United States, ² Department of Electrical and Computer Engineering, College of Engineering, Texas A&M University, College Station, TX, United States, ³ Department of Biomedical Engineering, College of Engineering, Texas A&M University, College Station, TX, United States

OPEN ACCESS

Edited by:

Charles Evans Wood,
University of Florida, United States

Reviewed by:

Leslie Myatt,
Oregon Health and Science
University, United States
Ronald R. Magness,
University of South Florida,
United States

*Correspondence:

Ramkumar Menon
ra2menon@utmb.edu
Arum Han
arum.han@ece.tamu.edu

Specialty section:

This article was submitted to
Embryonic and Developmental
Physiology,
a section of the journal
Frontiers in Physiology

Received: 03 April 2020

Accepted: 29 May 2020

Published: 30 June 2020

Citation:

Richardson L, Kim S, Menon R
and Han A (2020) Organ-On-Chip
Technology: The Future
of Feto-Maternal Interface Research?
Front. Physiol. 11:715.
doi: 10.3389/fphys.2020.00715

The placenta and fetal membrane act as a protective barrier throughout pregnancy while maintaining communication and nutrient exchange between the baby and the mother. Disruption of this barrier leads to various pregnancy complications, including preterm birth, which can have lasting negative consequences. Thus, understanding the role of the feto-maternal interface during pregnancy and parturition is vital to advancing basic and clinical research in the field of obstetrics. However, human subject studies are inherently difficult, and appropriate animal models are lacking. Due to these challenges, *in vitro* cell culture-based studies are most commonly utilized. However, the structure and functions of conventionally used *in vitro* 2D and 3D models are vastly different from the *in vivo* environment, making it difficult to fully understand the various factors affecting pregnancy as well as pathways and mechanisms contributing to term and preterm births. This limitation also makes it difficult to develop new therapeutics. The emergence of *in vivo*-like *in vitro* models such as organ-on-chip (OOC) platforms can better recapitulate *in vivo* functions and responses and has the potential to move this field forward significantly. OOC technology brings together two distinct fields, microfluidic engineering and cell/tissue biology, through which diverse human organ structures and functionalities can be built into a laboratory model that better mimics functions and responses of *in vivo* tissues and organs. In this review, we first provide an overview of the OOC technology, highlight two major designs commonly used in achieving multi-layer co-cultivation of cells, and introduce recently developed OOC models of the feto-maternal interface. As a vital component of this review, we aim to outline progress on the practicality and effectiveness of feto-maternal interface OOC (FM-OOC) models currently used and the advances they have fostered in obstetrics research. Lastly, we provide a perspective on the future basic research and clinical applications of FM-OOC models, and even those that integrate multiple organ systems into a single OOC system that may recreate intrauterine architecture in its entirety, which will accelerate our understanding of feto-maternal communication, induction of preterm labor, drug or toxicant permeability at this vital interface, and development of new therapeutic strategies.

Keywords: organ-on-a-chip, microfluidic lab-on-a-chip, fetal membrane, amniochorion, extracellular matrix

INTRODUCTION

The challenges and limitations in studying complex human organ or organ systems have spurred interdisciplinary collaboration to develop advanced human cell culture platforms that better mimic the structure and functions of human organ systems for studying their physiological and pathological processes. The combination of microfabrication, microfluidics, and induced pluripotent stem cell (iPSC) technologies has provided many physiological models that better mimic human anatomy, functions, and responses more accurately as seen *in vivo* than traditional 2D cell culture and some animal models (Liu et al., 2018; Sances et al., 2018; Ramme et al., 2019; Jagadeesan et al., 2020). These platforms, termed organ-on-chips (OOCs) or also called microphysiological systems (MPSs), can provide compartmentalized chambers that enable culturing and organizing cellular, extracellular matrices (ECMs), and other microenvironmental layers within these compartments (Huang et al., 2017; Mondrinos et al., 2017; Pasman et al., 2018), while still providing avenues for cellular signals, and sometimes even cells themselves, to migrate between the compartments through interconnected fluid paths (Ren et al., 2017; Richardson et al., 2019b). These systems allow researchers to test many different biomolecular factors under a more physiologically relevant *in vitro* environment, leading to a better understanding of human physiology through gathering significant amounts of data much faster and potentially much more cost-effectively (Huh, 2015; Maschmeyer et al., 2015; Gori et al., 2016; van der Helm et al., 2016; Bein et al., 2018; Guo et al., 2018; Carvalho et al., 2019). In the United States, significant investments made by the Defense Advanced Research Project Agency (DARPA) and the National Institutes of Health (NIH, especially the National Center for Advancing Translational Sciences) have spurred this area in the past decade. Currently, many pharmaceutical and biotechnology companies, as well as many government entities such as the NIH, the Food and Drug Administration (FDA), and Environmental Protection Agency (EPA) are actively interested in utilizing validated OOC systems to conduct pharmaceutical and chemical toxicity studies as well as collect pre-clinical data due to their ability in better replicating human physiology and responses (Capulli et al., 2014; Esch et al., 2015; Konar et al., 2016; Balijepalli and Sivaramakrishan, 2017).

While the goal of OOC technology is not to build whole living organs, these OOC systems are designed to establish a minimally functional unit of organ systems that can better recapitulate certain aspects of human physiology in *in vitro* model systems. Over the past decade, several studies have ushered in the era of OOC technology by replicating organs such as the heart (Zhang et al., 2015, 2016; Jastrzebska et al., 2016; Wan et al., 2018), lung (Huh, 2015; Konar et al., 2016; Shrestha et al., 2020), intestine (Kim et al., 2012; Bein et al., 2018; Guo et al., 2018), liver (Maschmeyer et al., 2015; Esch et al., 2016; Gori et al., 2016; Ramme et al., 2019), kidney (Maschmeyer et al., 2015; Wilmer et al., 2016; Ashammakhi et al., 2018; Ramme et al., 2019), skin (Maschmeyer et al., 2015; Materne et al., 2015; Mori et al., 2017; van den Broek et al., 2017; Bal-Ozturk et al., 2018), blood–brain barrier (BBB) (van der Helm et al., 2016; Jeong et al., 2018; Jagadeesan et al., 2020), bone (Hao et al., 2018; Truesdell et al.,

2020), eye (Dodson et al., 2015; Bennet et al., 2018; Haderspeck et al., 2019), and ovary (Nagashima et al., 2018; Weng et al., 2018), to name a few. For a more thorough review of currently available OOCs, refer to these reviews (An et al., 2015; Esch et al., 2015; Balijepalli and Sivaramakrishan, 2017; Low and Tagle, 2017; Kimura et al., 2018). Although they each started with simplistic models, each of these platforms has now been advanced to adapt novel physiologically relevant functions such as cellular contractions (i.e., heart, lung, and eye) (Huh, 2015; Qian et al., 2017; Seo et al., 2019), drug synthesis and excretion (i.e., liver and kidney) (Paoli and Samitier, 2016; Deng et al., 2019), barrier functions (i.e., skin and brain) (Jeong et al., 2018; Mieremet et al., 2019), dynamic flow of blood, air, or fluid interfaces (i.e., heart, lung) (Ribas et al., 2016; Artzy-Schnirman et al., 2019), and even co-culture with bacterial microbiomes (i.e., intestine) (Jalili-Firoozinezhad et al., 2019) in order to replicate the human organ systems of interest. In addition, multiple organ chips can be integrated, either physically through tubing or microfluidic channels or virtually by sending effluents from one OOC to another OOC, to create *in vitro* models of interconnected organ systems, with the ultimate goal of mimicking the entire human physiology (Maschmeyer et al., 2015; Materne et al., 2015; Kimura et al., 2018; Ramme et al., 2019).

From a basic science perspective, microfabricated microfluidic OOC platforms that replicate the microarchitecture of complex organ systems have opened up new experimental procedures to researchers that can utilize such platforms to study contributions of individual cells, cell–cell and cell–ECM interactions, and various biochemical factors to normal organ functions, and also how such functions are influenced by various factors that can be experimentally applied. Furthermore, these models can be extended to mimic a pathologic state, study disease physiology, and mechanisms of action, highlighting the usefulness of these devices in advancing our understanding of human physiology. The recent investments made by the US NIH (NCATS and many other NIH institutes) focusing on the development and utilization of disease OOCs are expected to advance this field further (Ronaldson-Bouchard and Vunjak-Novakovic, 2018; Ouchi et al., 2019; Park et al., 2019; Taylor et al., 2019; Vatine et al., 2019; Wang et al., 2019; Zhao et al., 2019).

From a clinical perspective, *in vitro* cell culture techniques and *in vivo*, small and large animal models, have been the backbone to collect pre-clinical data (Umscheid et al., 2011). The ever-increasing cost of new drug development, stemming in large part due to the large number of drugs that fail at the clinical trial phases due to toxicity or lack of efficacy, or which show conflicting results in animal models, have led to researchers beginning to look for methods that can better predict the toxicity and efficacy of potential drug compounds. OOCs are poised to fill this gap by providing physiologically relevant platforms for better modeling health and disease states of human organ systems. Currently, a variety of OOC platforms are being used in these settings, to model processes such as: (1) mode and mechanism of action, (2) pharmacokinetics and pharmacodynamics, (3) toxicity, (4) efficacy, and (5) dose–response (Luni et al., 2014; Abaci and Shuler, 2015; Esch et al., 2015; Ribas et al., 2016; Wilmer et al., 2016; Balijepalli and Sivaramakrishan, 2017;

Low and Tagle, 2017; Bal-Ozturk et al., 2018; Jodat et al., 2018; Kimura et al., 2018; Artzy-Schnirman et al., 2019; Haderspeck et al., 2019; Mittal et al., 2019; Pemathilaka et al., 2019b; van den Berg et al., 2019).

Although many fields have seen the development and advancement of OOC platforms to model physiological and pathological states of their organ systems of interest, the area of obstetrics is only now applying this emerging technique to study pregnancy and preterm birth (Blundell et al., 2016, 2018; Lee et al., 2016; Gnecco et al., 2017; Pemathilaka et al., 2019a,b; Richardson et al., 2019a; Yin et al., 2019). Unlike other single organ model systems, pregnancy introduces new fetal-derived organs within the mother's uterine cavity (i.e., placenta, umbilical cord, fetus, and fetal membranes) for a period of 9 months (Figure 1) (Menon et al., 2016; Richardson et al., 2018b). These new organs play an essential role in pregnancy maintenance, development, and induction of parturition. Two of these fetal-derived organs, namely, the placenta (Figures 2A,B; top dotted box) and fetal membrane (also known as amniochorion membrane or placenta membrane) (Figures 2B,C; bottom dotted box), create the feto-maternal interface throughout gestation; (1) between placenta and decidua basalis and (2) between fetal membranes and decidua parietalis. The decidua basalis is where implantation takes place and the basal plate is formed. This can be subdivided into a zona compacta and a zona spongiosa, where the detachment of the placenta takes place following birth. The decidua capsularis lies like a capsule around the chorion, while the decidua parietalis remains on the opposite uterus wall.





FIGURE 1 | Intra-uterine tissue anatomy. An illustration of the anatomy of the intra-uterine tissue broken down into maternal and fetal components. Maternal tissues comprise of the uterus (i.e., Myometrium), cervix, and vagina, while the fetal tissues include the placenta, umbilical cord, fetus, and fetal membranes.

Around the fourth month of gestation, the fetus is so large that the decidua capsularis comes into contact with the decidua parietalis. The merging of these two deciduae causes the uterine cavity to obliterate and forms the two feto-maternal interfaces. The placenta is comprised of the decidua basalis connected to the myometrium (gray), tertiary chorionic villi and intervillous space (light purple), and the reflective amniochorion membrane (blue and yellow cells). The placenta plays a critical role in maintaining pregnancy by regulating maternal metabolism, endocrine and immune functions in addition to providing blood flow [arteries (blue) and veins (red)], nutrients, and oxygen to the fetus, while removing waste products such as carbon dioxide (Jabareen et al., 2009; Mauri et al., 2013; Edey et al., 2018) (Figures 2A,B). The fetal membrane, which surrounds the baby throughout gestation, provides essential immune, endocrine, and mechanical functions (Figures 2B,C) that maintain pregnancy (Jabareen et al., 2009; Boldenow et al., 2013; Mauri et al., 2013, 2015; Perrini et al., 2015; Menon, 2016; Menon et al., 2016, 2017; Sato et al., 2016; Edey et al., 2018; Shah et al., 2019). They are comprised of two epithelial layers, the amnion (blue) and chorion (yellow), separated by an ECM containing mesenchymal cells (purple). The chorion layers are connected to the first layer of the decidua, termed the parietalis (green). As reviewed by Menon and Moore recently, this is one of the least studied intrauterine organs as it is often considered as an extension of the placenta or a dead tissue upon delivery (Menon et al., 2016). At term or preterm, redox imbalances within the intrauterine cavity induce a telomer-dependent, p38MAPK-mediated, cellular senescence in the amnion epithelial cells (AECs) (Figure 2C), which propagate damage-associated molecular patterns (DAMPs) and senescence-associated secretory phenotypes (SASPs) to the maternal decidua (Figure 2C), contributing to the initiation of labor (Menon et al., 2013, 2016; Behnia et al., 2015; Polettini et al., 2015; Sheller et al., 2016; Dixon et al., 2017; Hadley et al., 2018). Fetal membrane-derived signals are one of the essential fetal-derived messages of parturition at term and preterm (Menon et al., 2018; Menon, 2019). In this review, we will focus on the fetal membranes by (1) highlighting the conventionally utilized techniques to study their physiology and contribution to parturition, (2) discuss major design elements of OOCs that enable multi-layer co-cultivation of cells, (3) introduce recently developed feto-maternal interface OOC (FM-OOC) models, and (4) provide a perspective on the future development and impact of pregnancy-related OOCs in the field of obstetrics.

CURRENT METHODS TO STUDY THE FETO-MATERNAL INTERFACES AND THEIR LIMITATIONS

Fetal membranes (structure detailed in Figure 2C) are different from the placenta in terms of their origin, structure, cell types, and functions (Gude et al., 2004; Menon et al., 2018; Richardson et al., 2018b). Not surprisingly, due to these differences, the *in vivo* and *in vitro* models used to study these two distinct feto-maternal interfaces are also unique. Below we will discuss: (1) the similarities and differences between human anatomy




and commonly used large and small animal models and (2) the advantages and limitations to current *in vitro* and *ex vivo* techniques.

Limitations of Animal Models and Current *in vitro* and *ex vivo* Culture Techniques

Animal Models

Large and small animal models [i.e., non-human primates (NHP) and mice] are often used for fetal membrane studies. However, differences in pregnancy physiology and structure and uterine environment and cost to conduct studies often hamper the use of these models. NHP models most closely resemble the human fetal-maternal interface (Figure 3A), only deviation being the addition of densely packed fibrous layer covering the basal side of the amnion epithelium termed “microfibrils” (Figure 3B; dark green). These microfibrils could hinder communication between the AEC and ECM layers, which in humans have been shown to be vital for pregnancy maintenance and labor signaling at term. Apart from this, NHPs are anatomically and functionally the

most similar to humans, and serve as a reproducible model that enables longitudinal testing of experimental outcomes (Table 1). However, the limitations of this large animal model lie in: (1) the cost of each animal and future housing expenses, (2) handling difficulties, and (3) the need for a proper facility to conduct experiments (Table 1). While NHPs are the gold standard for large animal cytotoxicity studies, murine models such as CD1 and C57BL/6 mice are commonly utilized for small animal pre-clinical experiments. This is primarily due to the fact that murine experiments are easy to conduct, cost-effective, and have a short gestation (Table 1). Although valuable information can be gained from such models, the vast differences in anatomy (i.e., vasculature and maternal layers), and the induction of parturition (i.e., luteolysis), limit their use (Table 1). Regarding fetal-maternal interface anatomy, during murine gestation, the “amniotic sac” develops and surrounds each fetus, mimicking the fetal membrane. The amniotic sac is comprised of two epithelial layers; an amnion epithelial monolayer (blue in Figure 3C) and a multilayer chorion trophoblast cells (yellow in Figure 3C). Between these layers, loose collagen fibers support mesenchymal cells (purple in Figure 3C) and maternal blood vessels in the



ECM (**Figure 3C**). This tissue does not contain a maternal interface (i.e., decidua), other than maternal blood flow, like other mammalian models. These anatomical differences are the biggest hindrance when conducting physiological or pharmaceutical related experiments in murine systems.

A full list of the advantages and limitations of each model described in this section can be found in **Table 1**, and the anatomical differences can be seen in **Figure 3**.

Cell Sources for *in vitro* Models

The standard in fetal membrane research is maintaining membranes as explants *in vitro* (Fortunato et al., 1994) or culturing primary cells (Menon et al., 2013; Sheller et al., 2016; Hadley et al., 2018; Jin et al., 2018; Richardson et al., 2020b), both obtained from discarded human fetal membranes dissected after placental delivery. Though this brings in patient-to-patient variability (**Table 1**), these approaches maintain some of the *in vivo* characteristics such as cytoskeletal organization (Menon et al., 2018; Richardson et al., 2018b, 2020b), endocrine and paracrine signaling (Myatt and Sun, 2010; Behnia et al., 2015), inflammatory responses (Menon et al., 2009; Noda-Nicolau et al., 2016), as well as immune regulatory factors (Fortunato et al., 1998, 2001). Protocols documenting amnion (i.e., AEC and AMC) cell isolation techniques are well established

(Kendal-Wright, 2007; Menon et al., 2013; Sato et al., 2016; Jin et al., 2018). However, although it is not impossible to isolate and culture primary chorion mesenchymal and trophoblast cells (CMC and CT) [99, 108], due to many *in vitro* challenges (isolation, culture conditions, passage-related issues, and transition properties), researchers have turned to use immortalized placenta-based trophoblast cells (i.e., BEWO and JEG-3) derived from carcinomas to replicate this layer [109]. As fetal membrane CTs reside in a functionally different region and perform distinct functions than placental trophoblast, the use of placental trophoblasts-derived cell lines to study chorionic membrane trophoblast functions are not ideal. The various cell types and cell sources that could be utilized to study the fetal membranes and feto-maternal interface are summarized in **Table 1**, together with their advantages and limitations.

In vitro Cell Culture Techniques

Two-dimensional (2D) single cell type culture experiments are most easy to run and low cost, and thus broadly utilized (Kendal-Wright, 2007; Menon et al., 2013; Meng et al., 2016; Sato et al., 2016; Feng et al., 2018b; Hadley et al., 2018; Jin et al., 2018). However, regardless of the cell origin (i.e., primary or immortalized) or cell layer (i.e., amnion or chorion), the major drawback is the limitations stemming from studying only a small

part of the whole organ. Co-culturing two or more cell types allow researchers to study the organ system in a more holistic way, including studying cell–cell and cell–ECM interactions. Transwell co-culture is the current standard protocol to represent the amnion (i.e., AEC and AMC), amniochorion (i.e., AEC and CT or BEWO), and the feto-maternal interface (i.e., AEC and decidua) (Blanco et al., 2009; Talayev et al., 2010; Magatti et al., 2015; Wu et al., 2017; Lee et al., 2018; Richardson et al., 2019a). Despite providing a much more physiologically relevant model compared to 2D mono- or mixed culture, transwell culture has a variety of limitations, as summarized in **Table 1**.

Ex vivo Tissue Culture Techniques

Culturing fetal membrane tissues or biopsy-based explants obtained from discarded human fetal membrane from scheduled cesarean deliveries are commonly utilized for tissue-level culture and studies (Fortunato et al., 1994; Menon et al., 2011; Menon et al., 2014; Richardson et al., 2017a; Ayad et al., 2018). Additionally, live fetal membrane samples can be mounted into imaging chambers allowing for cellular and collagen visualization over time. Along with traditional explant treatments, these studies mimic biomechanical stressors, such as stretch, in order to delineate membrane weakening leading to rupture. These types of experiments enable a variety of molecular and biochemical assays using a more physiologically relevant model system and thus have significantly contributed to our current knowledge of fetal membrane physiology in the field (Fortunato et al., 1994; Miller and Loch-Carusio, 2010; Uchide et al., 2012; Boldenow et al., 2013; Menon et al., 2014; Kumar et al., 2016; Martin et al., 2017; Feng et al., 2018a; Hung et al., 2019). While explant culture maintains many advantages compared to other *in vitro* techniques, there are also many limitations, as summarized in **Table 1**.

CO-CULTURE ORGAN-ON-CHIP DESIGNS AND FUNCTIONS

Most organ systems are composed of two or more cell types that are arranged in a specific way to create various microarchitectures, where these multiple cell types closely interact and function together, giving rise to the unique structure and functions of each organ system (Bhatia and Ingber, 2014; An et al., 2015; Huh, 2015; van der Helm et al., 2016; Wilmer et al., 2016; Bein et al., 2018; Jodat et al., 2018; Sances et al., 2018). To recapitulate such complex multi-cellular structures, the majority of OOC systems (also called tissue chips or MPSs) require two or more different cell types to be co-cultured in specific arrangements. In addition, various interstitial flow (Artzy-Schnirman et al., 2019) and blood flow also directly access these multi-cellular architectures in a specific way (Ribas et al., 2016); thus, the multiple cell culture compartments of OOCs also need to be accessed by various fluids, creating distinct microenvironments for each cell types and cellular layers. In addition to cells, various ECMs secreted by cells are also significant components of most organ systems (Mondrinos et al., 2017; Pasman et al., 2018). Thus, OOCs have also to consider incorporating physiologically relevant ECMs. For all

OOC systems, it is also essential to be able to monitor the cells and their microenvironment. Thus, being compatible with microscopy is critical. In addition, easy fluidic access to each cell layer, for both applying various biochemical stimuli and being able to analyze secreted metabolites, are also necessary. Here, we first provide a review of typical co-culture OOC architectures, and ECMs used, followed by examples of currently available OOC systems representing the feto-maternal interface.

Co-culture OOC Architectures


Most co-culture OOCs fall under two design categories, “vertical” or “planar” co-culture designs, termed based on the orientation of the multiple microfluidic culture chambers that comprises the OOC (**Figure 4**). Each design has unique advantages and disadvantages, which are described below.

Multi-layered vertical co-culture OOCs are designed to contain vertically stacked cell culture chambers separated by a porous membrane (**Figure 4A**). Here, a semipermeable membrane separates the two vertically positioned cell culture chambers (**Figure 4A**; black arrow), allowing cells to be confined within each cell culture chamber while allowing biochemicals to flow through the membrane freely. This membrane often mimics the basement membrane layer and collagen, thus enabling cell–cell and cell–collagen interactions in the OOC environment (Pasman et al., 2018). The most commonly utilized membranes are the commercially available track-etched polyethylene terephthalate (PET) membrane, the same membrane utilized in transwell culture. These membranes come in varieties of different pore sizes, which can be selected to control the permeability between the cell culture compartments and can also mimic *in vivo* collagen density (i.e., pore size). These membranes can be coated with various ECMs collagens, partially recreating the cell–ECM interface. The two cell types can also be cultured on both sides of this membrane, minimizing the distances between the two cell types and allow better cell–cell interactions. Since these membranes are typically around 10 μm thick (Pasman et al., 2018) and made of plastic, and thus more rigid and thicker than what may be seen *in vivo* (i.e., 2 kPa and $13.4 \pm 2.42 \mu\text{m}$ thick) (Halfter et al., 2013; Richardson et al., 2017b), custom membranes that are more thinner than commercially available ones have also been developed for OOC applications (Sip and Folch, 2014; Mondrinos et al., 2017; Pasman et al., 2018). The vertically positioned co-culture chambers can be fabricated with various materials (i.e., glass, polycarbonate, polyurethanes) and by multiple microfabrication processes (i.e., soft-lithography, laser engraving, CAD-based machining, and 3D printing), providing flexibility for various OOC applications. Overall, the vertical co-culture OOC design structurally mimics the *in vivo* structure, which is one of the major advantages of this design. Several OOC devices mimicking organs such as the lung, gut, and BBB utilize this design (**Table 2**) (Kim et al., 2012; Esch et al., 2016; Jeong et al., 2018).

Despite these features and advantages, two significant limitations of this design are: (1) imaging of each cell culture compartment is relatively difficult due to the difficulty of imaging through the membrane that prevents imaging both cell types and (2) due to its multilayer design, microfabrication steps are more

TABLE 1 | Benefits and limitation of *in vivo* and *in vitro* fetal membrane methodology.

Model		Sub-type	Benefits	Limitations	
<i>In vivo</i>	Murine		<ul style="list-style-type: none"> • Cost-effective • Easy to handle • Longitudinal sample available 	<ul style="list-style-type: none"> • Anatomical differences • Parturition initiation differences • Small sample size per pup • Large pup number • Endocrine differences • Not cost-effective • Expensive to maintain Hard to handle 	
	Non-human primate		<ul style="list-style-type: none"> • Anatomical similarities • Parturition initiation similarities • Longitudinal sample availability • Reliable large animal model • Small fetal number 		
	Human		<ul style="list-style-type: none"> • Preferred primary source • Correct anatomy • Parturition initiation standard 	<ul style="list-style-type: none"> • Clinical trial difficult • Hard to acquire samples • Require infrastructure to store samples properly • Difficult to collect longitudinal samples 	
	2D cell culture	Sing cell type culture	Primary cells	<ul style="list-style-type: none"> • Human cells • Physiologically relevant • Maintain <i>in vivo</i> characteristics 	<ul style="list-style-type: none"> • Patient-to-patient variability • Difficult to culture • Only studying a part of the whole tissue
<i>In vitro</i>	2D cell culture	Sing cell type culture	Immortalized human cells	<ul style="list-style-type: none"> • Derived from human cells • Sustainable in culture 	<ul style="list-style-type: none"> • Have to prove physiological relevance • <i>n vivo</i> characteristics lost • Only studying a part of the whole tissue
	Transwell co-culture	Multi-cell type mixed culture			
		Co-culture		<ul style="list-style-type: none"> • Ability to study cell–cell interactions 	<ul style="list-style-type: none"> • All cell types are mixed together • Hard to determine signal initiation
				<ul style="list-style-type: none"> • Ability to study cell–cell or cell–collagen interactions • Ability to study signaling propagation and barrier function 	<ul style="list-style-type: none"> • Difficult to culture cells on both sides the membrane • Low throughput • High signal-to-noise ratio • Cell type limitations • Difficult to expand beyond two cell type co-culture
	3D cell culture	Spheroids		<ul style="list-style-type: none"> • 3D growths of cells • Better maintain <i>in vivo</i> characteristics • High throughput • Mixed co-culture possible 	<ul style="list-style-type: none"> • Small cell number leads to limited phenotypic assays • Time-consuming to form • Not uniform • May not organize properly into proper organ structure
	3D cell culture	Cell sheets		<ul style="list-style-type: none"> • Full amnion layer • Can be cultured longer than amnion explants Easy to image 	<ul style="list-style-type: none"> • Very fragile • Only mimic the amnion layer • Lacks uniformity •
Whole tissue	3D cell printing		<ul style="list-style-type: none"> • Can recreate multiple feto-maternal interface layers • Proper tissue organization • Uniform production 	<ul style="list-style-type: none"> • Can apply unwanted shear stress to cells during printing • Time-consuming to characterize for each cell type and ECMs to be printed Have not been demonstrated for feto-maternal interface yet 	
	Explant culture		<ul style="list-style-type: none"> • Correct tissue organization • Mimics <i>in vivo</i> signaling 	<ul style="list-style-type: none"> • Hard to acquire samples • Require infrastructure to store samples properly • Only culturable for up to 72 h or less 	



complicated and also reliable sealing of this sandwich structure is challenging. This also means that mimicking any organ structure that is composed of three or more cell layers, which is the case of the fetal membrane and feto-maternal interface, requires assembling multiple such sandwich structures, which pose even more challenges. This could significantly limit its applicability in many complex organ systems. In contrast, a planar co-culture design is ideal for cell visualization and fluid control because all the layers are on the same plane.

Planar co-culture OOCs are designed to contain parallel cell culture chambers separated by porous gel or microchannel arrays (Huh et al., 2011; Gumuscu et al., 2017; Richardson et al., 2019b), all in the same plane (**Figure 4B**). Here, the gel or microchannel array functions as a porous barrier that keeps cells within each cell culture chamber, while allowing various biochemicals to diffuse through. In the case of gel barrier-based systems, gel guiding microstructures (e.g., micropillar array or micro steps) are utilized so that the gel barrier fills only the space between the two culture chambers and prevents the gels that are being loaded to spill over and into the culture chambers (Vickerman et al., 2008; Chung et al., 2009; Funamoto et al., 2012; Osaki et al., 2020; Poussin et al., 2020). Here, the type of gel utilized, and its porosity determine how easily biochemicals can diffuse between the culture compartments. Another design strategy uses arrays of microfluidic channels that are small enough to prevent

cells from moving from one compartment to the other (however, still allowing cell migration), but large enough for biochemicals to diffuse through. In this design, the length, size, and number of microfluidic channels control the degree of diffusion. These microfluidic channels can also be filled with various ECM components. In both cases, this gel barrier or microfluidic channel filled with ECM mimics a basement membrane and collagen layer that cells can actively degrade as seen *in vivo*, thus enabling cell–cell and cell–collagen interactions in the OOC environment (Richardson et al., 2019b; Osaki et al., 2020; Poussin et al., 2020). A major advantage of these planar designs is its compatibility and ease in microscopic imaging, as all structures are in the same focal plane and transparent. This makes it also ideal for identifying and monitoring cell–cell communication under different physiological environments, which is often challenging in vertical designs. The planar microfluidic designs are most commonly made out of polydimethylsiloxane (PDMS), but various other plastic that can minimize molecular adsorption can also be utilized (Berthier et al., 2012; Wang et al., 2012). These designs have been used extensively in OOC devices, such as those that mimic organs like the gut, liver, and multiorgan systems (**Table 2**) (Maschmeyer et al., 2015; Gori et al., 2016; Guo et al., 2018; Carvalho et al., 2019; Yin et al., 2019). Limitations of these planar designs also exist, such as difficulty in recreating tight junction barrier formation such as the BBB, and the larger

TABLE 2 | Examples of current co-culture OOC models that utilize vertical or planar co-culture designs.

Lab group	Name of chip	Structure	Functionality	Cell types	Number of chambers	Journal name and year
Maschmeyer et al.	Microfluidic four-organ chip	Planar	Human intestine, liver, skin and kidney co-culture to test drug metabolism	Human HepaRG cell line Human primary hepatic stellate cell (HHStEC) Human proximal tubule cell line (RPTEC/TERT-1) Reconstructed human small intestinal barrier Human juvenile prepuce	6	Lab on a Chip, 2015
Carvalho et al.	Colorectal tumor-on-a-chip	Planar	Precision nanomedicine delivery to a colorectal tumor	HCT-116 cancer cell Human colonic microvascular endothelial cell (HCoMEC)	2	Science Advances, 2019
Y. Guo et al.	Biomimetic gut-on-a-chip	Planar	Drug metabolism in the intestine	Caco-2 cell	Four replicate chambers	Artificial Organs, 2018
Gori et al.	Non-alcoholic fatty liver disease-on-a-chip	Planar	Mimicking non-alcoholic fatty liver disease to understand how it can lead to hepatocellular carcinoma	Human hepatoma HepG2/C3A cell	2	PLOS One, 2016
F. Yin et al.	3D human placenta-on-a-chip	Planar	Establishment of 3D placental barrier and placental response to nanoparticle exposure <i>in vitro</i>	BeWo cell Human choriocarcinoma cell Human umbilical vein endothelial cell (HUVEC)	2	Toxicology <i>in Vitro</i> , 2019
Jeong et al.	3D blood–brain barrier model	Vertical	Blood–brain barrier function and permeability measurements	Primary astrocyte cell Mouse brain endothelial cell (C57BL/6)	2	IEEE Transactions on Medical Engineering, 2018
Esch et al.	Modular body-on-a-chip	Vertical	Model drug metabolism in the GI tract epithelium and 3D primary liver tissue	Caco-2 Cell Non-parenchymal cell (NPC)	2	Lab on a Chip, 2016
Kim et al.	Human gut-on-a-chip	Vertical	Mimic the flow and microbial flora environment of the gut	Caco-2 Cell Human Caco-2 intestinal epithelial cell (Caco-2BBE)	2	Lab on a Chip, 2012
Huh et al.	Lung-on-a-chip	Vertical	Recreate the lung and test biological function	Human alveolar epithelial cell Microvascular endothelial cell	2	Science, 2010

distances between the co-culture compartments compared to the vertical co-culture OOC designs.

As summarized here, both co-culture OOC designs have been extensively utilized, with no one system being the perfect design, both having several advantages and disadvantages. This means that each OOC system design, even if mimicking the same organ system, must be decided based on what type of experiments researchers need to run and what kind of measurements are needed for such experiments. Understanding the “fit for purpose” concept when designing any OOC system becomes critical, as no one system can completely mimic the complex human organ system. In addition to these two designs, bioprinting of cells or scaffolds can also be utilized to create co-culture OOC devices

(Miri et al., 2019; Mittal et al., 2019), but no such OOC devices of fetal membrane and feto-maternal interface exist as of yet, thus are not included in this review.

***In vitro* Extracellular Matrices**

In vertical co-culture OOC designs, synthetic membranes (e.g., track-etched PET membrane) are widely used to mimic the basement membrane (Sip and Folch, 2014; Mondrinos et al., 2017; Pasman et al., 2018) and regulate the communication between the two cell culture compartments. However, such synthetic membranes are quite different from the *in vivo* basement membrane, which is a key biological factor and plays many roles (Guller et al., 1995; Bryant-Greenwood, 1998; Strauss,

2013; Richardson et al., 2017a,b). Due to these reasons, synthetic membranes used in OOC systems are also often coated with various ECM materials to better mimic the *in vivo* environment (Pasman et al., 2018). However, this also makes it more challenging to control the porosity and diffusion characteristics, thus communication between the two cell layers. In planar co-culture OOC designs, gel barriers and microchannel array act as porous membranes. To better mimic the *in vivo* basement membrane, these microchannels can be filled with ECM materials (Bryant-Greenwood, 1998; Richardson et al., 2017b). Often, optimization of the type and concentration of ECMs loaded into this microchannel array is required to ensure the proper control over molecular diffusion and cell migration.

For OOCs to mimic the feto-maternal interface, co-culture OOC designs are a perfect candidate to recapitulate its microarchitecture and functionality under physiological and pathological conditions since the feto-maternal interface is composed of seven different cellular layers, some with ECMs and some without ECMs (van Herendaal et al., 1978; Bryant-Greenwood, 1998; Avila et al., 2014; Richardson et al., 2017b; Menon et al., 2018). Such co-culture OOC models can mimic the feto-maternal interface and enable a better understanding of their physiology as well as how they are affected by drugs, toxicants, or other biochemical signaling factors.

Fetal Membrane OOC (FM-OOC) Models

The first OOC to recreate components of the fetal membranes (i.e., the feto-maternal interface) was published in early 2019 (Richardson et al., 2019a). The FM-OOC was designed to better understand cellular interactions and paracrine cross-talk between maternal and fetal cells during pregnancy and parturition (Richardson et al., 2019a). The FM-OOC platform utilized the vertical co-culture OOC design and was composed of two orthogonal vertically stacked cell culture chambers containing equal surface areas. Primary AECs were seeded on top (fetal side), and primary decidual cells were placed on the bottom (maternal side). These chambers were separated by a semipermeable polycarbonate membrane (Figure 5A). The FM-OOC was utilized to detect membrane permeability, oxidative stress, and toxin-induced senescence, as well as cytokine production (Figure 5A). This device has many advantages over traditional transwell culture systems, including its ability to: (1) maintain physical and fluidic isolation between cell layers, (2) promote detectable biochemical changes, (3) better reproducibility, and (4) utilize fewer reagents and cells (Katt et al., 2016; Richardson et al., 2019a). However, it is still missing many vital components to recreate either the fetal membrane or the feto-maternal interface, such as (1) semipermeable membrane lacks ECM components to mimic that seen *in utero* (Richardson et al., 2019a), (2) organization of the device does not permit for imaging of both chambers, (3) direct imaging of migrating cells between chambers is not possible, where such cell migration is critical for understanding feto-maternal interface remodeling, and (4) lacks many cellular components of the feto-maternal interface, such as the AMCs, CMCs, and CTs (Richardson et al., 2017b, 2018b). Continuous advancement of FM-OOC models is expected, with the eventual goal to recreate the entire fetal

membrane in OOC format. This device will be utilized to promote the study of cellular interactions during pregnancy and parturition, screening of drugs, and to advance research activities to reduce the risk of pregnancy-associated complications.

Amnion Membrane OOC (AM-OOC) Models

To address the imaging limitations of the previously developed FM-OOC model described above, as well as focus more on the amnion membrane, which alone contains two cellular layers (Figure 2C), recently an amnion membrane OOC (AM-OOC) system was developed, the first of its kind (Richardson et al., 2019b). The AM-OOC system utilizes a planar parallel co-culture OOC model design, having two circular culture chambers with interconnected microchannel array in between that functions as a controlled permeable barrier between the compartments (Figure 5B) (Richardson et al., 2019b). By culturing primary human AECs in the outer circular chamber and AMCs in the inner circular chamber, separated by Type IV collagen-filled microchannels mimicking the basement membrane, they were able to recreate the amnion membrane on an OOC format (Richardson et al., 2019b) (Figure 5B). Here, primary AECs and AMCs obtained from the midzones of term not in labor fetal membranes were utilized. This model was successfully utilized to show the interactive and transitional properties of amnion cells (epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition; Richardson and Menon, 2018; Richardson et al., 2018a, 2020b) under normal and oxidative stress conditions, similar to how they behave and respond *in utero* (Richardson et al., 2019b) (Figure 5B). Although this planar device allowed for easy cell imaging of both compartments as well as direct monitoring and tracking of migratory cells between compartments, there were still aspects that did not fully recreate the amnion membrane. For example, the AMCs were cultured in 2D, while *in utero* they are embedded in 3D collagen. Also, the system did not contain all of the four cell types and layers of the fetal membranes.

PERSPECTIVE

Proposed Ideas for a Full Feto-Maternal Interface OOC Model

Although the field currently has two established co-culture OOC models (Richardson et al., 2019a,b) (Figure 5), significant advances need to be made to better study and understand the feto-maternal interface as a whole using an OOC model. Some advanced fetal membrane models have recently been suggested, although not developed yet, to better recapitulate the fetal and maternal side of the feto-maternal interface (Gnecco et al., 2017). The proposed device contains four vertical chambers, each chamber containing AECs, trophoblast cells, decidua, and bacteria (Gnecco et al., 2017) (Figure 6A). Here, with the help of media perfusion, immune cells (i.e., macrophages and leukocytes) are envisioned to be added to the chorio-decidua layers of this model to recreate an





FIGURE 5 | Currently developed OOCs mimicking components of the fetal membranes and feto-maternal interface. **(A)** Device layout—schematic of the two-chamber fetal membrane-organ-on-chip (FM-OO-C) developed to study fetal and maternal cell interactions at the fetal membrane interface adapted from Richardson et al. (2019a). The FM-OO-C is comprised of two stacked PDMS cell culture chambers that are coated with Matrigel (pink). Primary AECs (blue) are placed in the top chamber and grown on top of a polycarbonate semipermeable synthetic membrane, while primary decidual cells (green) are placed in the lower chamber and grown on the glass substrate. **(B)** Images of the fabricated FM-OO-C chips and cells being cultured within each compartment. Bright-field microscopy images of primary human AECs in the top chamber (purple) and primary decidual cells in the bottom chamber (red) are shown. The yellow outline visualizes the cellular morphology. **(C)** Endpoint assays—Left: Fluorescein isothiocyanate stain (yellow) is seen in the two horizontal columns feeding into the top AEC chamber. Media were collected from the bottom vertical columns to measure membrane permeability. Center: Bottom chamber showing representative senescence-associated β -galactosidase (SA- β -Gal) stained decidual cells and the semipermeable membrane containing blue staining representing SA- β -Gal + AECs. Right: Image of the FM-OO-C containing media from both amnion and decidual cells, which can be used to measure cytokine kinetics. **(D)** Device layout—the amnion membrane organ-on-chip (AM-OO-C) is designed to recreate the amnion component of the fetal membrane by co-culturing AECs (blue) in an outer circular PDMS chamber and AMCs (purple) in the inner circular chamber. This planar two-chamber model is separated by a type IV collagen-filled (pink) microchannel array (mimicking the basement membrane). **(E)** The outer chamber of the AM-OO-C was filled with red dye, and the inner chamber was filled with blue dye for visualization. Bright-field microscopy images of AEC morphology and AMC morphology inside an AM-OO-C device. Microchannels filled with Type IV collagen Matrigel (stained with Masson trichrome), connecting the two culture chambers, are also shown. **(F)** Endpoint assay—confocal images showing native AECs (green) and AMCs (red), which have transitioned, migrated, and integrated into the opposite population. Middle right panel highlights (yellow) GFP-AECs that have migrated through the type IV collagen-filled microchannel, re-localized vimentin, and transitioned into a mesenchymal morphology indicative of EMT. Middle left panels highlight (yellow) RFP-AMCs that have migrated through the type IV collagen-filled microchannel, down-regulated vimentin, and transitioned into an epithelial morphology indicative of MET. The bottom panel is a schematic representing AECs (green) and AMCs (red) undergoing cellular transitions. Gray arrows highlight the migration direction. Pink, vimentin; green, histone 2B AEC; red, histone 2B AMCs. This figure is a rendition of Richardson et al. (2019b). All figures reused with permission.

infectious preterm birth model (Gnecco et al., 2017) (**Figure 6A**). Although this design takes into consideration the cell density ratio seen *in vivo*, it does not contain amnion or chorion mesenchymal cells within the ECM of the fetal membranes, nor does it recreate any ECM components or cell–collagen interactions (**Table 3**). However, it does, for the first time, propose a four-chambered OOC model and discuss the importance of immune cell activation in preterm birth; both of these components deem this OOC novel and ahead of its time in 2017.

An alternative FM-OO-C model proposed here would utilize a four-chamber planar co-culture OOC design, culturing primary AECs, AMCs, CMSs/CTs, and decidual cells (**Figure 6B**). Interconnecting each culture chamber can be an array of microchannels that are filled with ECMs, recreating the amnion and chorion basement membrane. Additionally, AMCs and CMCs/CTs can be suspended in Matrigel and/or decellularized amnion collagen, creating 3D cultures in these compartments (**Figure 6B**). Such a model would utilize OOC technology to recreate the microarchitecture



of the fetomaternal interface down to every cell and collagen layer (Richardson et al., 2017b) (**Figure 2C** and **Table 3**). However, this device still lacks critical cellular components, including maternal and fetal immune cells, as well as the maternal layer of the decidua (parietalis). Integration of these cell layers along with biomechanical stressors (i.e., stretch) are needed in order to mimic the physiology of the fetomaternal interface.

Following the successful development of such a model, creating a pathologic condition of the fetomaternal interface, i.e., a disease OOC model, would be the next step. Such a disease model can mimic ascending and descending infection and inflammation, and be utilized to determine the propagation of infectious (e.g., lipopolysaccharides or bacteria) or inflammatory signals from maternal to fetal side, or vice versa, and test the efficacy of potential therapeutic compounds (i.e., anti-inflammatory molecules or synthetic drugs) in suppressing inflammation in each layer. Importantly, employing such a disease OOC model can contribute to the development of novel therapeutics against preterm birth, a very much needed area of developing considering that around 9.8% people in the United States alone are affected (Goldenberg et al., 2008; Liew et al., 2008; Beck et al., 2010; Blencowe et al., 2013; Lawn et al., 2013) while having the potential to significantly reduce the time and cost associated with pre-clinical and

clinical trials. However, like any other model system, the developed OOCs also have several limitations, including: (1) each OOC is designed to answer certain biological questions, limiting their universal use, (2) requirements for specialized equipment to fabricate and conduct experiments, although this is not becoming easier, (3) have the tendency to be lower throughput, and (4) multi-organ chips are not available to model pregnancy.

Next Steps for Pregnancy-Related *in vitro* Methodologies

Although OOCs relating to the field of obstetrics are emerging over the past 5 years (Blundell et al., 2016, 2018; Lee et al., 2016; Gnecco et al., 2017; Nagashima et al., 2018; Pemathilaka et al., 2019a,b; Richardson et al., 2019a,b; Yin et al., 2019), significant future research is needed in order to truly create an *in vitro* pregnancy model to better understand fetomaternal communication, the induction of term and preterm labor, and drug or toxicant permeability at these vital interfaces. Advances from traditional 2D culture systems to novel 3D culture platforms are contributing to overcoming these knowledge gaps. 3D cell culture, typically referred to as an organoid culture [i.e., cell spheroids (Okere et al., 2015), cell sheets (Richardson et al., 2020a), or tissue printing (Kang et al., 2016)], utilizes cell

TABLE 3 | Characteristics of the proposed OOCs compared to *in vitro* and *in vivo* conditions.

Characteristics	Cell type	2D cell culture	3D cell culture	IFMOC	FMI-OOC	Mice models	Non-human primate	Human
Morphology	AEC	Cuboidal/fibroblastoid	Fibroblastoid	Cuboidal/fibroblastoid	Cuboidal/fibroblastoid	Cuboidal/fibroblastoid	Cuboidal/fibroblastoid	Cuboidal/fibroblastoid
	AMC	Fibroblastoid	Cuboidal/fibroblastoid	Not present	Fibroblastoid	Fibroblastoid	Fibroblastoid	Fibroblastoid
	GMC/CT	Fibroblastoid/cuboidal	Fibroblastoid/cuboidal	Only contain cuboidal CTs,	Fibroblastoid/cuboidal	Only contain cuboidal CTs,	Fibroblastoid/cuboidal	Fibroblastoid/cuboidal
Collagen production	DECI	Fibroblastoid	Fibroblastoid	Fibroblastoid	Fibroblastoid	Not connected,	Fibroblastoid	Fibroblastoid
	AEC	Low,	High	High	High	High	High	High
	AMC	High	High	High	High	High	High	High
Intermediate filament expression	GMC/CT	Low,	High	High	High	High	High	High
	DECI	Low	Low	Low	Low	Low	Low	Low
	AEC	Metastate	Mesenchymal	Metastate	Metastate	Metastate	Metastate	Metastate
	AMC	Mesenchymal	Metastate	Not present,	Mesenchymal	Mesenchymal	Mesenchymal	Mesenchymal
	GMC/CT	Mesenchymal/epithelial	Mesenchymal/epithelial	Only contain epithelial CTs,	Mesenchymal/epithelial	Only contain epithelial CTs,	Mesenchymal/epithelial	Mesenchymal/epithelial
	DECI	Mesenchymal	Mesenchymal	Mesenchymal	Mesenchymal	Not connected,	Mesenchymal	Mesenchymal

Red font indicates differences.

aggregates either with single cell type or multiple cell types, often together with various ECMs, to recreate components of the fetal membrane and feto-maternal interface (Liu and Qi, 2010; Davydova et al., 2011; Shieh et al., 2017). While 3D growth of cells has been documented in many fields to induce expression of more *in vivo* characteristics and functionality, only a handful of studies have been conducted with fetal membrane-derived cells. Importantly, no attempts have been made so far to recreate the fetal membrane or feto-maternal interfaces using such 3D bioprinting techniques that have been utilized to print volumetric shapes of cell and collagen layers to recreate ear, noses, and eye components (Kuru et al., 2016; Isaacson et al., 2018; Jodat et al., 2020). The advantages and limitations of each of these 3D culture techniques are also summarized in **Table 1**.

Impact to Clinical Research

Although many clinical studies have been conducted evaluating different aspects of fetal membranes, it is still challenging under certain settings to acquire approval and or recruit enough patients within individual clinical conditions (i.e., preeclampsia, pPROM, chorioamnionitis, gestational diabetes) in order to provide tissue for basic research and/or to conduct clinical trials [162, 163]. A “pregnancy-on-chip” platform that can represent various pathologic conditions of pregnancy could provide a useful model to conduct clinical trials that generally could not occur. This model is also ideal for testing FDA-approved drugs that currently do not contain enough pre-clinical data related to transport across the feto-maternal interfaces. This cost-effective approach could lead to the approval of dozens of drugs to be repurposed toward treating pregnancy-related complications. Additionally, OOC-based studies can be adapted to clinical research to conduct experiments that can lead to better understand the mechanism of drug functions (e.g., efficacy, cytotoxicity, passage through distinct layers of the feto-maternal interfaces), and be utilized for pre-clinical trials of therapeutic development against preterm birth, or even replace part of a clinical trial.

Besides, the recent European Union (EU) ban on animal testing for cosmetic products (No Author, 2013), as well as US EPA's current directive that prioritizes efforts to reduce animal testing, are expected to further spur this area. The development of novel OOC models suggests two new promising concepts: (1) “personalized medicine-on-chip” by using patient-derived cells, including primary cells and inducing patient-derived fat cells into iPSCs, which can consider the effect of patient-to-patient variability (Jodat et al., 2018; van den Berg et al., 2019) and (2) applying the “human-on-chip” concepts to clinical trials (Luni et al., 2014; Abaci and Shuler, 2015; Maschmeyer et al., 2015).

Impact on Basic Research

The many challenges in this area are not just faced clinically but also while conducting basic biological research. Current, *in vitro* (i.e., 2D, 3D, or transwell culture) and *ex vivo* (i.e., explant culture) assays provide complexity in understanding multi-organ communication between individual cellular or collagen layers within the tissue and or organ-to-organ systems (**Tables 1, 3**). Understanding this communication is vital to answering

physiological questions related to gestation, term, and preterm parturition, as well as the pharmaceutical questions related to pre-clinical trials. Furthermore, understanding individual cellular contribution to labor onset and adverse pregnancy outcomes could potentially identify novel biomarkers of term and preterm delivery. Biomarkers identified in this manner could lead to the development of standard clinic testing for patients having a risk for preterm labor.

CONCLUSION

Organ-on-chips represent a variety of physiological and pathophysiological states of diverse organ structures that are contributing to a better understanding of complex organ systems. These platforms also have the potential to become critical steps in the drug discovery pipeline, as well as part of the future of bench to bedside research. Although the importance of the feto-maternal interface in pregnancy has been documented for decades, only recently has the technology allowed for novel *in vitro* techniques to recreate the anatomy and function of the placenta and fetal membranes accurately. Several placenta-on-chip (Blundell et al., 2016, 2018; Lee et al., 2016; Pemathilaka

et al., 2019a,b; Yin et al., 2019) and fetal membrane-on-chip (Richardson et al., 2019a,b) platforms have emerged by mimicking the microarchitecture and functions of both feto-maternal interfaces, and are improving our understanding of this vital organ system. As more advanced OOC models of the feto-maternal interface emerge, we expect such models to radically change how research and development are conducted in the field of obstetrics.

AUTHOR CONTRIBUTIONS

LR and SK drafted the manuscript and created the figures, while AH and RM reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

LR is a Kempner Fellow supported by the University of Texas Medical Branch in Galveston, Texas. This study was supported by the NICHD grant (Grant No. 1R03HD098469-01) to RM and the NICHD grant (Grant No. R01 HD100729) to RM and AH.

REFERENCES

- Abaci, H. E., and Shuler, M. L. (2015). Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling. *Integr. Biol. (Camb)* 7, 383–391. doi: 10.1039/c4ib00292j
- An, F., Qu, Y., Liu, X., Zhong, R., and Luo, Y. (2015). Organ-on-a-chip: new platform for biological analysis. *Anal. Chem. Insights* 10, 39–45. doi: 10.4137/aci.s28905
- Artzy-Schnirman, A., Hobi, N., Schneider-Daum, N., Guenat, O. T., Lehr, C. M., and Sznitman, J. (2019). Advanced in vitro lung-on-chip platforms for inhalation assays: From prospect to pipeline. *Eur. J. Pharm. Biopharm.* 144, 11–17. doi: 10.1016/j.ejpb.2019.09.006
- Ashammakhi, N., Wesseling-Perry, K., Hasan, A., Elkhammas, E., and Zhang, Y. S. (2018). Kidney-on-a-chip: untapped opportunities. *Kidney Int.* 94, 1073–1086. doi: 10.1016/j.kint.2018.06.034
- Avila, C., Santorelli, J., Mathai, J., Ishkin, S., Jabsky, M., Willins, J., et al. (2014). Anatomy of the fetal membranes using optical coherence tomography: part 1. *Placenta* 35, 1065–1069. doi: 10.1016/j.placenta.2014.09.011
- Ayad, M. T., Taylor, B. D., and Menon, R. (2018). Regulation of p38 mitogen-activated kinase-mediated fetal membrane senescence by statins. *Am. J. Reprod. Immunol.* 80:e12999. doi: 10.1111/aji.12999
- Balijepalli, A., and Sivaramakrishnan, V. (2017). Organs-on-chips: research and commercial perspectives. *Drug Discov. Today* 22, 397–403. doi: 10.1016/j.drudis.2016.11.009
- Bal-Ozturk, A., Miccoli, B., Avci-Adali, M., Mogtader, F., Sharifi, F., Cecen, B., et al. (2018). Current strategies and future perspectives of skin-on-a-chip platforms: innovations, technical challenges and commercial outlook. *Curr. Pharm. Des.* 24, 5437–5457. doi: 10.2174/1381612825666190206195304
- Beck, S., Wojdyla, D., Say, L., Betran, A. P., Merialdi, M., Requejo, J. H., et al. (2010). The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. *Bull. World Health Organ.* 88, 31–38. doi: 10.2471/blt.08.062554
- Behnia, F., Taylor, B. D., Woodson, M., Kacerovsky, M., Hawkins, H., Fortunato, S. J., et al. (2015). Chorionic membrane senescence: a signal for parturition? *Am. J. Obstet. Gynecol.* 213, e1–e16. doi: 10.1016/j.ajog.2015.05.041
- Bein, A., Shin, W., Jalili-Firoozinezhad, S., Park, M. H., Sontheimer-Phelps, A., Tovaglieri, A., et al. (2018). Microfluidic organ-on-a-chip models of human intestine. *Cell. Mol. Gastroenterol. Hepatol.* 5, 659–668. doi: 10.1016/j.jcmgh.2017.12.010
- Bennet, D., Estlack, Z., Reid, T., and Kim, J. (2018). A microengineered human corneal epithelium-on-a-chip for eye drops mass transport evaluation. *Lab Chip* 18, 1539–1551. doi: 10.1039/c8lc00158h
- Berthier, E., Young, E. W., and Beebe, D. (2012). Engineers are from PDMS-land, biologists are from polystyrenia. *Lab Chip* 12, 1224–1237. doi: 10.1039/c2lc20982a
- Bhatia, S. N., and Ingber, D. E. (2014). Microfluidic organs-on-chips. *Nat. Biotechnol.* 32, 760–772. doi: 10.1038/nbt.2989
- Blanco, O., Leno-Duran, E., Morales, J. C., Olivares, E. G., and Ruiz-Ruiz, C. (2009). Human decidual stromal cells protect lymphocytes from apoptosis. *Placenta* 30, 677–685. doi: 10.1016/j.placenta.2009.05.011
- Blencowe, H., Cousens, S., Chou, D., Oestergaard, M., Say, L., Moller, A. B., et al. (2013). Born too soon: the global epidemiology of 15 million preterm births. *Reprod. Health* 10(Suppl. 1):S2. doi: 10.1186/1742-4755-10-s1-s2
- Blundell, C., Tess, E. R., Schanzer, A. S., Coutifaris, C., Su, E. J., Parry, S., et al. (2016). A microphysiological model of the human placental barrier. *Lab Chip* 16, 3065–3073. doi: 10.1039/c6lc00259e
- Blundell, C., Yi, Y. S., Ma, L., Tess, E. R., Farrell, M. J., Georgescu, A., et al. (2018). Placental drug transport-on-a-chip: a microengineered in vitro model of transporter-mediated drug efflux in the human placental barrier. *Adv. Healthc. Mater.* 7:10.1002/adhm.201700786. doi: 10.1002/adhm.201700786
- Boldenow, E., Jones, S., Lieberman, R. W., Chames, M. C., Aronoff, D. M., Xi, C., et al. (2013). Antimicrobial peptide response to group B Streptococcus in human extraplacental membranes in culture. *Placenta* 34, 480–485. doi: 10.1016/j.placenta.2013.02.010
- Bryant-Greenwood, G. D. (1998). The extracellular matrix of the human fetal membranes: structure and function. *Placenta* 19, 1–11. doi: 10.1016/s0143-4004(98)90092-3
- Capulli, A. K., Tian, K., Mehandru, N., Bukhta, A., Choudhury, S. F., Suchyta, M., et al. (2014). Approaching the in vitro clinical trial: engineering organs on chips. *Lab Chip* 14, 3181–3186. doi: 10.1039/c4lc00276h
- Carvalho, M. R., Barata, D., Teixeira, L. M., Giselbrecht, S., Reis, R. L., Oliveira, J. M., et al. (2019). Colorectal tumor-on-a-chip system: A 3D tool for precision onco-nanomedicine. *Sci. Adv.* 5:eaaw1317. doi: 10.1126/sciadv.aaw1317
- Chung, S., Sudo, R., Mack, P. J., Wan, C. R., Vickerman, V., and Kamm, R. D. (2009). Cell migration into scaffolds under co-culture conditions

- in a microfluidic platform. *Lab Chip* 9, 269–275. doi: 10.1039/b807585a
- Davydova, D. A., Voroteliak, E. A., Bragina, E. E., Terskikh, V. V., and Vasil'ev, A. V. (2011). [Culture of human amniotic fluid stem cells in 3D collagen matrix]. *Tsitologiya* 53, 325–331.
- Deng, J., Wei, W., Chen, Z., Lin, B., Zhao, W., Luo, Y., et al. (2019). Engineered liver-on-a-chip platform to mimic liver functions and its biomedical applications: a review. *Micromachines (Basel)* 10:676. doi: 10.3390/mi10100676
- Dixon, C. L., Richardson, L., Sheller-Miller, S., Saade, G., and Menon, R. (2017). A distinct mechanism of senescence activation in amnion epithelial cells by infection, inflammation, and oxidative stress. *Am. J. Reprod. Immunol.* 79:10.1111/aji.12790. doi: 10.1111/aji.12790
- Dodson, K. H., Echevarria, F. D., Li, D., Sappington, R. M., and Edd, J. F. (2015). Retina-on-a-chip: a microfluidic platform for point access signaling studies. *Biomed. Microdevices* 17:114. doi: 10.1007/s10544-015-0019-x
- Edey, L. F., Georgiou, H., O'Dea, K. P., Mesiano, S., Herbert, B. R., Lei, K., et al. (2018). Progesterone, the maternal immune system and the onset of parturition in the mouse. *Biol. Reprod.* 98, 376–395. doi: 10.1093/biolre/iox146
- Esch, E. W., Bahinski, A., and Huh, D. (2015). Organs-on-chips at the frontiers of drug discovery. *Nat. Rev. Drug Discov.* 14, 248–260. doi: 10.1038/nrd4539
- Esch, M. B., Ueno, H., Applegate, D. R., and Shuler, M. L. (2016). Modular, pumpless body-on-a-chip platform for the co-culture of GI tract epithelium and 3D primary liver tissue. *Lab Chip* 16, 2719–2729. doi: 10.1039/c6lc00461j
- Feng, L., Allen, T. K., Marinello, W. P., and Murtha, A. P. (2018b). Roles of progesterone receptor membrane component 1 in oxidative stress-induced aging in chorion cells. *Reprod. Sci.* 26, 394–403. doi: 10.1177/1933719118776790
- Feng, L., Allen, T. K., Marinello, W. P., and Murtha, A. P. (2018a). Infection-induced thrombin production: a potential novel mechanism for preterm premature rupture of membranes (PPROM). *Am. J. Obstet. Gynecol.* 219:101.e1–e12. doi: 10.1016/j.ajog.2018.04.014
- Fortunato, S. J., Menon, R., and Lombardi, S. J. (1998). The effect of transforming growth factor and interleukin-10 on interleukin-8 release by human amniochorion may regulate histologic chorioamnionitis. *Am. J. Obstet. Gynecol.* 179(3 Pt 1), 794–799. doi: 10.1016/s0002-9378(98)70085-7
- Fortunato, S. J., Menon, R., Lombardi, S. J., and LaFleur, B. (2001). Interleukin-10 inhibition of gelatinases in fetal membranes: therapeutic implications in preterm premature rupture of membranes. *Obstet. Gynecol.* 98, 284–288. doi: 10.1016/s0029-7844(01)01441-7
- Fortunato, S. J., Menon, R., Swan, K. F., and Lyden, T. W. (1994). Organ culture of amniochorionic membrane in vitro. *Am. J. Reprod. Immunol.* 32, 184–187. doi: 10.1111/j.1600-0897.1994.tb01112.x
- Funamoto, K., Zervantonakis, I. K., Liu, Y., Ochs, C. J., Kim, C., and Kamm, R. D. (2012). A novel microfluidic platform for high-resolution imaging of a three-dimensional cell culture under a controlled hypoxic environment. *Lab Chip* 12, 4855–4863. doi: 10.1039/c2lc40306d
- Gnecco, J. S., Anders, A. P., Cliffl, D., Pensabene, V., Rogers, L. M., Osteen, K., et al. (2017). Instrumenting a fetal membrane on a chip as emerging technology for preterm birth research. *Curr. Pharm. Des.* 23, 6115–6124. doi: 10.2174/1381612823666170825142649
- Goldenberg, R. L., Culhane, J. F., Iams, J. D., and Romero, R. (2008). Epidemiology and causes of preterm birth. *Lancet* 371, 75–84. doi: 10.1016/s0140-6736(08)60074-4
- Gori, M., Simonelli, M. C., Giannitelli, S. M., Businaro, L., Trombetta, M., and Rainer, A. (2016). Investigating nonalcoholic fatty liver disease in a liver-on-a-chip microfluidic device. *PLoS One* 11:e0159729. doi: 10.1371/journal.pone.0159729
- Gude, N. M., Roberts, C. T., Kalionis, B., and King, R. G. (2004). Growth and function of the normal human placenta. *Thromb. Res.* 114, 397–407. doi: 10.1016/j.thromres.2004.06.038
- Guller, S., Kong, L., Wozniak, R., and Lockwood, C. J. (1995). Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes. *J. Clin. Endocrinol. Metab.* 80, 2244–2250. doi: 10.1210/jcem.80.7.7608287
- Gumusc, B., Albers, H. J., van den Berg, A., Eijkel, J. C. T., and van der Meer, A. D. (2017). Compartmentalized 3D tissue culture arrays under controlled microfluidic delivery. *Sci. Rep.* 7:3381. doi: 10.1038/s41598-017-01944-5
- Guo, Y., Li, Z., Su, W., Wang, L., Zhu, Y., and Qin, J. A. (2018). Biomimetic human gut-on-a-chip for modeling drug metabolism in intestine. *Artif. Organs* 42, 1196–1205. doi: 10.1111/aor.13163
- Haderspeck, J. C., Chuchuy, J., Kustermann, S., Liebau, S., and Loskill, P. (2019). Organ-on-a-chip technologies that can transform ophthalmic drug discovery and disease modeling. *Expert. Opin. Drug Discov.* 14, 47–57. doi: 10.1080/17460441.2019.1551873
- Hadley, E. E., Sheller-Miller, S., Saade, G., Salomon, C., Mesiano, S., Taylor, R. N., et al. (2018). Amnion epithelial cell-derived exosomes induce inflammatory changes in uterine cells. *Am. J. Obstet. Gynecol.* 219:478.e1–e21. doi: 10.1016/j.ajog.2018.08.021
- Halfter, W., Candiello, J., Hu, H., Zhang, P., Schreiber, E., and Balasubramani, M. (2013). Protein composition and biomechanical properties of in vivo-derived basement membranes. *Cell Adh. Migr.* 7, 64–71. doi: 10.4161/cam.22479
- Hao, S., Ha, L., Cheng, G., Wan, Y., Xia, Y., Sosnoski, D. M., et al. (2018). A Spontaneous 3D bone-on-a-chip for bone metastasis study of breast cancer cells. *Small* 14:e1702787. doi: 10.1002/smll.201702787
- Huang, G., Li, F., Zhao, X., Ma, Y., Li, Y., Lin, M., et al. (2017). Functional and biomimetic materials for engineering of the three-dimensional cell microenvironment. *Chem. Rev.* 117, 12764–12850. doi: 10.1021/acs.chemrev.7b00094
- Huh, D., Hamilton, G. A., and Ingber, D. E. (2011). From 3D cell culture to organs-on-chips. *Trends Cell Biol.* 21, 745–754. doi: 10.1016/j.tcb.2011.09.005
- Huh, D. D. (2015). A human breathing lung-on-a-chip. *Ann. Am. Thorac. Soc.* 12(Suppl. 1), S42–S44. doi: 10.1513/AnnalsATS.201410-442MG
- Hung, T. H., Chen, S. F., Wu, C. H., Kao, C. C., and Wu, C. P. (2019). Increased soluble epoxide hydrolase in human gestational tissues from pregnancies complicated by acute chorioamnionitis. *Mediators Inflamm.* 2019:8687120. doi: 10.1155/2019/8687120
- Isaacson, A., Swioklo, S., and Connon, C. J. (2018). 3D bioprinting of a corneal stroma equivalent. *Exp. Eye Res.* 173, 188–193. doi: 10.1016/j.exer.2018.05.010
- Jabareen, M., Mallik, A. S., Bilic, G., Zisch, A. H., and Mazza, E. (2009). Relation between mechanical properties and microstructure of human fetal membranes: an attempt towards a quantitative analysis. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 144(Suppl. 1), S134–S141. doi: 10.1016/j.ejogrb.2009.02.032
- Jagadeesan, S., Workman, M. J., Herland, A., Svendsen, C. N., and Vatine, G. D. (2020). Generation of a human iPSC-Based blood-brain barrier chip. *J. Vis. Exp.* 157:e60925. doi: 10.3791/60925
- Jalili-Firoozinezhad, S., Gazzaniga, F. S., Calamari, E. L., Camacho, D. M., Fadel, C. W., Bein, A., et al. (2019). A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip. *Nat. Biomed. Eng.* 3, 520–531. doi: 10.1038/s41551-019-0397-0
- Jastrzebska, E., Tomecka, E., and Jesion, I. (2016). Heart-on-a-chip based on stem cell biology. *Biosens. Bioelectron.* 75, 67–81. doi: 10.1016/j.bios.2015.08.012
- Jeong, S., Kim, S., Buonocore, J., Park, J., Welsh, C. J., Li, J., et al. (2018). A three-dimensional arrayed microfluidic blood-brain barrier model with integrated electrical sensor array. *IEEE Trans. Biomed. Eng.* 65, 431–439. doi: 10.1109/tbme.2017.2773463
- Jin, J., Richardson, L., Sheller-Miller, S., Zhong, N., and Menon, R. (2018). Oxidative stress induces p38MAPK-dependent senescence in the fetomaternal interface cells. *Placenta* 67, 15–23. doi: 10.1016/j.placenta.2018.05.008
- Jodat, Y. A., Kang, M. G., Kiaee, K., Kim, G. J., Martinez, A. F. H., Rosenkranz, A., et al. (2018). Human-derived organ-on-a-chip for personalized drug development. *Curr. Pharm. Des.* 24, 5471–5486. doi: 10.2174/1381612825666190308150055
- Jodat, Y. A., Kiaee, K., Vela Jarquin, D., De la Garza Hernandez, R. L., Wang, T., Joshi, S., et al. (2020). A 3D-printed hybrid nasal cartilage with functional electronic olfaction. *Adv. Sci. (Weinh)* 7:1901878. doi: 10.1002/adv.201901878
- Kang, H. W., Lee, S. J., Ko, I. K., Kengla, C., Yoo, J. J., and Atala, A. (2016). A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. *Nat. Biotechnol.* 34, 312–319. doi: 10.1038/nbt.3413
- Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S., and Searson, P. C. (2016). In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform. *Front. Bioeng. Biotechnol.* 4:12. doi: 10.3389/fbioe.2016.00012
- Kendal-Wright, C. E. (2007). Stretching, mechanotransduction, and proinflammatory cytokines in the fetal membranes. *Reprod. Sci.* 14(8 Suppl), 35–41. doi: 10.1177/1933719107310763

- Kim, H. J., Huh, D., Hamilton, G., and Ingber, D. E. (2012). Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. *Lab Chip* 12, 2165–2174. doi: 10.1039/c2lc40074j
- Kimura, H., Sakai, Y., and Fujii, T. (2018). Organ/body-on-a-chip based on microfluidic technology for drug discovery. *Drug Metab. Pharmacokinet.* 33, 43–48. doi: 10.1016/j.dmpk.2017.11.003
- Konar, D., Devarasetty, M., Yildiz, D. V., Atala, A., and Murphy, S. V. (2016). Lung-on-a-chip technologies for disease modeling and drug development. *Biomed. Eng. Comput. Biol.* 7(Suppl. 1), 17–27. doi: 10.4137/becb.s34252
- Kumar, D., Moore, R. M., Mercer, B. M., Mansour, J. M., Redline, R. W., and Moore, J. J. (2016). The physiology of fetal membrane weakening and rupture: Insights gained from the determination of physical properties revisited. *Placenta* 42, 59–73. doi: 10.1016/j.placenta.2016.03.015
- Kuru, I., Maier, H., Muller, M., Lenarz, T., and Lueth, T. C. (2016). A 3D-printed functioning anatomical human middle ear model. *Hear. Res.* 340, 204–213. doi: 10.1016/j.heares.2015.12.025
- Lawn, J. E., Kinney, M. V., Belizan, J. M., Mason, E. M., McDougall, L., Larson, J., et al. (2013). Born too soon: accelerating actions for prevention and care of 15 million newborns born too soon. *Reprod. Health* 10(Suppl. 1):S6. doi: 10.1186/1742-4755-10-s1-s6
- Lee, H. J., Nam, S. M., Choi, S. K., Seo, K. Y., Kim, H. O., and Chung, S. H. (2018). Comparative study of substrate free and amniotic membrane scaffolds for cultivation of limbal epithelial sheet. *Sci. Rep.* 8:14628. doi: 10.1038/s41598-018-32914-0
- Lee, J. S., Romero, R., Han, Y. M., Kim, H. C., Kim, C. J., Hong, J. S., et al. (2016). Placenta-on-a-chip: a novel platform to study the biology of the human placenta. *J. Matern. Fetal. Neonatal. Med.* 29, 1046–1054. doi: 10.3109/14767058.2015.1038518
- Liew, G., Wang, J. J., and Mitchell, P. (2008). Preterm birth, long-term survival, and fertility. *JAMA* 300:167. doi: 10.1001/jama.300.2.167-a
- Liu, C., Oikonomopoulos, A., Sayed, N., and Wu, J. C. (2018). Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond. *Development* 145:dev156166. doi: 10.1242/dev.156166
- Liu, F., and Qi, H. B. (2010). [Utility of amniotic cells plus collagen I complex for fetal membrane healing]. *Zhonghua Yi Xue Za Zhi* 90, 1933–1935.
- Low, L. A., and Tagle, D. A. (2017). Organs-on-chips: progress, challenges, and future directions. *Exp. Biol. Med. (Maywood)* 242, 1573–1578. doi: 10.1177/1535370217700523
- Luni, C., Serena, E., and Elvassore, N. (2014). Human-on-chip for therapy development and fundamental science. *Curr. Opin. Biotechnol.* 25, 45–50. doi: 10.1016/j.copbio.2013.08.015
- Magatti, M., Caruso, M., De Munari, S., Vertua, E., De, D., Manuelpillai, U., et al. (2015). Human amniotic membrane-derived mesenchymal and epithelial cells exert different effects on monocyte-derived dendritic cell differentiation and function. *Cell Transplant.* 24, 1733–1752. doi: 10.3727/096368914x684033
- Martin, L. F., Moco, N. P., de Lima, M. D., Poletini, J., Miot, H. A., Correa, C. R., et al. (2017). Histologic chorioamnionitis does not modulate the oxidative stress and antioxidant status in pregnancies complicated by spontaneous preterm delivery. *BMC Pregnancy Childbirth* 17:376. doi: 10.1186/s12884-017-1549-4
- Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hubner, J., et al. (2015). A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. *Lab Chip* 15, 2688–2699. doi: 10.1039/c5lc00392j
- Materne, E. M., Maschmeyer, I., Lorenz, A. K., Horland, R., Schimek, K. M., Busek, M., et al. (2015). The multi-organ chip—a microfluidic platform for long-term multi-tissue coculture. *J. Vis. Exp.* 98:e52526. doi: 10.3791/52526
- Mauri, A., Perrini, M., Ehret, A. E., De Focatiis, D. S., and Mazza, E. (2015). Time-dependent mechanical behavior of human amnion: macroscopic and microscopic characterization. *Acta Biomater.* 11, 314–323. doi: 10.1016/j.actbio.2014.09.012
- Mauri, A., Perrini, M., Mateos, J. M., Maake, C., Ochsenbein-Koelble, N., Zimmermann, R., et al. (2013). Second harmonic generation microscopy of fetal membranes under deformation: normal and altered morphology. *Placenta* 34, 1020–1026. doi: 10.1016/j.placenta.2013.09.002
- Meng, Y., Murtha, A. P., and Feng, L. (2016). Progesterone, inflammatory cytokine (TNF-alpha), and oxidative stress (H2O2) regulate progesterone receptor membrane component 1 expression in fetal membrane cells. *Reprod. Sci.* 23, 1168–1178. doi: 10.1177/1933719116630412
- Menon, R. (2016). Human fetal membranes at term: dead tissue or signalers of parturition? *Placenta* 44, 1–5. doi: 10.1016/j.placenta.2016.05.013
- Menon, R. (2019). Initiation of human parturition: signaling from senescent fetal tissues via extracellular vesicle mediated paracrine mechanism. *Obstet. Gynecol. Sci.* 62, 199–211. doi: 10.5468/ogs.2019.62.4.199
- Menon, R., Boldogh, I., Hawkins, H. K., Woodson, M., Poletini, J., Syed, T. A., et al. (2014). Histological evidence of oxidative stress and premature senescence in preterm premature rupture of the human fetal membranes recapitulated in vitro. *Am. J. Pathol.* 184, 1740–1751. doi: 10.1016/j.ajpath.2014.02.011
- Menon, R., Boldogh, I., Urrabaz-Garza, R., Poletini, J., Syed, T. A., Saade, G. R., et al. (2013). Senescence of primary amniotic cells via oxidative DNA damage. *PLoS One* 8:e83416. doi: 10.1371/journal.pone.0083416
- Menon, R., Bonney, E. A., Condon, J., Mesiano, S., and Taylor, R. N. (2016). Novel concepts on pregnancy clocks and alarms: redundancy and synergy in human parturition. *Hum. Reprod. Update* 22, 535–560. doi: 10.1093/humupd/dmw022
- Menon, R., Fortunato, S. J., Yu, J., Milne, G. L., Sanchez, S., Drobek, C. O., et al. (2011). Cigarette smoke induces oxidative stress and apoptosis in normal term fetal membranes. *Placenta* 32, 317–322. doi: 10.1016/j.placenta.2011.01.015
- Menon, R., Mesiano, S., and Taylor, R. N. (2017). Programmed fetal membrane senescence and exosome-mediated signaling: a mechanism associated with timing of human parturition. *Front. Endocrinol. (Lausanne)* 8:196. doi: 10.3389/fendo.2017.00196
- Menon, R., Peltier, M. R., Eckardt, J., and Fortunato, S. J. (2009). Diversity in cytokine response to bacteria associated with preterm birth by fetal membranes. *Am. J. Obstet. Gynecol.* 201:306.e1–e6. doi: 10.1016/j.ajog.2009.06.027
- Menon, R., Richardson, L. S., and Lappas, M. (2018). Fetal membrane architecture, aging and inflammation in pregnancy and parturition. *Placenta* 79, 40–45. doi: 10.1016/j.placenta.2018.11.003
- Mieremet, A., Vazquez Garcia, A., Boiten, W., van Dijk, R., Gooris, G., Bouwstra, J. A., et al. (2019). Human skin equivalents cultured under hypoxia display enhanced epidermal morphogenesis and lipid barrier formation. *Sci. Rep.* 9:7811. doi: 10.1038/s41598-019-44204-4
- Miller, M. F., and Loch-Carusio, R. (2010). Comparison of LPS-stimulated release of cytokines in punch versus transwell tissue culture systems of human gestational membranes. *Reprod. Biol. Endocrinol.* 8:121. doi: 10.1186/1477-7827-8-121
- Miri, A. K., Mostafavi, E., Khorsandi, D., Hu, S. K., Malpica, M., and Khademhosseini, A. (2019). Bioprinters for organs-on-chips. *Biofabrication* 11:042002. doi: 10.1088/1758-5090/ab2798
- Mittal, R., Woo, F. W., Castro, C. S., Cohen, M. A., Karanxha, J., Mittal, J., et al. (2019). Organ-on-chip models: implications in drug discovery and clinical applications. *J. Cell. Physiol.* 234, 8352–8380. doi: 10.1002/jcp.27729
- Mondrinos, M. J., Yi, Y. S., Wu, N. K., Ding, X., and Huh, D. (2017). Native extracellular matrix-derived semipermeable, optically transparent, and inexpensive membrane inserts for microfluidic cell culture. *Lab Chip* 17, 3146–3158. doi: 10.1039/c7lc00317j
- Mori, N., Morimoto, Y., and Takeuchi, S. (2017). Skin integrated with perfusable vascular channels on a chip. *Biomaterials* 116, 48–56. doi: 10.1016/j.biomaterials.2016.11.031
- Myatt, L., and Sun, K. (2010). Role of fetal membranes in signaling of fetal maturation and parturition. *Int. J. Dev. Biol.* 54, 545–553. doi: 10.1387/ijdb.082771lm
- Nagashima, J. B., El Assal, R., Songsasen, N., and Demirci, U. (2018). Evaluation of an ovary-on-a-chip in large mammalian models: species specificity and influence of follicle isolation status. *J. Tissue Eng. Regen. Med.* 12, e1926–e1935. doi: 10.1002/term.2623
- No Author, (2013). EU: final ban on animal experiments for cosmetic ingredients implemented. *Altex* 30, 268–269.
- Noda-Nicolau, N. M., Poletini, J., Peltier, M. R., da Silva, M. G., and Menon, R. (2016). Combinations and loads of bacteria affect the cytokine production by fetal membranes: an in vitro study. *Am. J. Reprod. Immunol.* 76, 504–511. doi: 10.1111/aji.12596
- Okere, B., Alviano, F., Costa, R., Quagliano, D., Ricci, F., Dominici, M., et al. (2015). In vitro differentiation of human amniotic epithelial cells into insulin-producing 3D spheroids. *Int. J. Immunopathol. Pharmacol.* 28, 390–402. doi: 10.1177/0394632015588439
- Osaki, T., Uzel, S. G. M., and Kamm, R. D. (2020). On-chip 3D neuromuscular model for drug screening and precision medicine in neuromuscular disease. *Nat. Protoc.* 15, 421–449. doi: 10.1038/s41596-019-0248-1

- Ouchi, R., Togo, S., Kimura, M., Shinozawa, T., Koido, M., Koike, H., et al. (2019). Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. *Cell Metab.* 30:374–384.e6. doi: 10.1016/j.cmet.2019.05.007
- Owiti, G. E., Tarara, R. P., and Hendrickx, A. G. (1989). Fetal membranes and placenta of the African green monkey (*Cercopithecus aethiops*). *Anat. Embryol. (Berl)* 179, 591–604. doi: 10.1007/bf00315701
- Paoli, R., and Samitier, J. (2016). Mimicking the kidney: a key role in organ-on-chip development. *Micromachines (Basel)* 7:126. doi: 10.3390/mi7070126
- Park, S. J., Zhang, D., Qi, Y., Li, Y., Lee, K. Y., Bezzerides, V. J., et al. (2019). Insights Into the pathogenesis of catecholaminergic polymorphic ventricular tachycardia from engineered human heart tissue. *Circulation* 140, 390–404. doi: 10.1161/circulationaha.119.039711
- Pasman, T., Grijpma, D., Stamatialis, D., and Poot, A. (2018). Flat and microstructured polymeric membranes in organs-on-chips. *J. R. Soc. Interface* 15:20180351. doi: 10.1098/rsif.2018.0351
- Pemathilaka, R. L., Caplin, J. D., Aykar, S. S., Montazami, R., and Hashemi, N. N. (2019a). Placenta-on-a-chip: in vitro study of caffeine transport across placental barrier using liquid chromatography mass spectrometry. *Glob. Chall.* 3:1800112. doi: 10.1002/gch2.201800112
- Pemathilaka, R. L., Reynolds, D. E., and Hashemi, N. N. (2019b). Drug transport across the human placenta: review of placenta-on-a-chip and previous approaches. *Interface Focus* 9:20190031. doi: 10.1098/rsfs.2019.0031
- Perrini, M., Mauri, A., Ehret, A. E., Ochsenbein-Kolble, N., Zimmermann, R., Ehrbar, M., et al. (2015). Mechanical and microstructural investigation of the cyclic behavior of human amnion. *J. Biomech. Eng.* 137:061010. doi: 10.1115/1.4030054
- Poletti, J., Behnia, F., Taylor, B. D., Saade, G. R., Taylor, R. N., and Menon, R. (2015). Telomere fragment induced amnion cell senescence: a contributor to parturition? *PLoS One* 10:e0137188. doi: 10.1371/journal.pone.0137188
- Poussin, C., Kramer, B., Lanz, H. L., Van den Heuvel, A., Laurent, A., Olivier, T., et al. (2020). 3D human microvessel-on-a-chip model for studying monocyte-to-endothelium adhesion under flow – application in systems toxicology. *Altx* 37, 47–63. doi: 10.14573/altex.1811301
- Qian, F., Huang, C., Lin, Y. D., Ivanovskaya, A. N., O'Hara, T. J., Booth, R. H., et al. (2017). Simultaneous electrical recording of cardiac electrophysiology and contraction on chip. *Lab Chip* 17, 1732–1739. doi: 10.1039/c7lc00210f
- Ramme, A. P., Koenig, L., Hasenberg, T., Schwenk, C., Magauer, C., Faust, D., et al. (2019). Autologous induced pluripotent stem cell-derived four-organ-chip. *Future Sci. OA* 5:Fso413. doi: 10.2144/fsoa-2019-0065
- Ren, X., Levin, D., and Lin, F. (2017). Cell migration research based on organ-on-chip-related approaches. *Micromachines (Basel)* 8:324. doi: 10.3390/mi8110324
- Ribas, J., Sadeghi, H., Manbachi, A., Leijten, J., Brinegar, K., Zhang, Y. S., et al. (2016). Cardiovascular organ-on-a-chip platforms for drug discovery and development. *Appl. In Vitro Toxicol.* 2, 82–96. doi: 10.1089/aivt.2016.0002
- Richardson, L., Dixon, C. L., Aguilera-Aguirre, L., and Menon, R. (2018a). Oxidative Stress-Induced TGF-beta/TAB1-mediated p38MAPK activation in human amnion epithelial cells. *Biol. Reprod.* 99, 1100–1112. doi: 10.1093/biolre/i0y135
- Richardson, L., Gnecco, J., Ding, T., Osteen, K., Rogers, L., Aronoff, D., et al. (2019a). Fetal membrane organ-on-chip: an innovative approach to study cellular interactions. *Reprod. Sci.* [Epub ahead of print].
- Richardson, L., Jeong, S., Kim, S., Han, A., and Menon, R. (2019b). Amnion membrane organ-on-chip: an innovative approach to study cellular interactions. *FASEB J.* 33, 8945–8960. doi: 10.1096/fj.201900020RR
- Richardson, L., Martin, L., and Menon, R. (2018b). “Characteristics, properties, and functionality of fetal membranes: an overlooked area in the field of parturition,” in *Proceedings of the 5th International Conference on Advances in Skin, Wound Care and Tissue Science & 14th International Conference on Clinical Dermatology. Encyclopedia of Reproduction 2017*, 2nd Edn, Rome.
- Richardson, L., and Menon, R. (2018). Proliferative, migratory, and transition properties reveal metastate of human amnion cells. *Am. J. Pathol.* 188, 2004–2015. doi: 10.1016/j.ajpath.2018.05.019
- Richardson, L., Vargas, G., Brown, T., Ochoa, L., Trivedi, J., Kacerovskı, M., et al. (2017b). Redefining 3Dimensional placental membrane microarchitecture using multiphoton microscopy and optical clearing. *Placenta* 53, 66–75. doi: 10.1016/j.placenta.2017.03.017
- Richardson, L. S., Menon, P. R., and Menon, R. (2020a). The effects of extracellular matrix rigidity on 3-dimensional cultures of amnion membrane cells. *Placenta* 90, 82–89. doi: 10.1016/j.placenta.2019.12.008
- Richardson, L. S., Taylor, R. N., and Menon, R. (2020b). Reversible EMT and MET mediate amnion remodeling during pregnancy and labor. *Sci. Signal.* 13:eaay1486. doi: 10.1126/scisignal.aay1486
- Richardson, L., Vargas, G., Brown, T., Ochoa, L., Sheller-Miller, S., Saade, G. R., et al. (2017a). Discovery and characterization of human amniotic membrane microfractures. *Am. J. Pathol.* 187, 2821–2830. doi: 10.1016/j.ajpath.2017.08.019
- Ronaldson-Bouchard, K., and Vunjak-Novakovic, G. (2018). Organs-on-a-chip: a fast track for engineered human tissues in drug development. *Cell Stem Cell* 22, 310–324. doi: 10.1016/j.stem.2018.02.011
- Sances, S., Ho, R., Vatine, G., West, D., Laperle, A., Meyer, A., et al. (2018). Human iPSC-derived endothelial cells and microengineered organ-chip enhance neuronal development. *Stem Cell Rep.* 10, 1222–1236. doi: 10.1016/j.stemcr.2018.02.012
- Sato, B. L., Collier, E. S., Vermudez, S. A., Junker, A. D., and Kendal-Wright, C. E. (2016). Human amnion mesenchymal cells are pro-inflammatory when activated by the Toll-like receptor 2/6 ligand, macrophage-activating lipoprotein-2. *Placenta* 44, 69–79. doi: 10.1016/j.placenta.2016.06.005
- Seo, J., Byun, W. Y., Alisafaei, F., Georgescu, A., Yi, Y. S., Massaro-Giordano, M., et al. (2019). Multiscale reverse engineering of the human ocular surface. *Nat. Med.* 25, 1310–1318. doi: 10.1038/s41591-019-0531-2
- Shah, N. M., Lai, P. F., Imami, N., and Johnson, M. R. (2019). Progesterone-related immune modulation of pregnancy and labor. *Front. Endocrinol. (Lausanne)* 10:198. doi: 10.3389/fendo.2019.00198
- Sheller, S., Papaconstantinou, J., Urrabaz-Garza, R., Richardson, L., Saade, G., Salomon, C., et al. (2016). Amnion-epithelial-cell-derived exosomes demonstrate physiologic state of cell under oxidative stress. *PLoS One* 11:e0157614. doi: 10.1371/journal.pone.0157614
- Shieh, H. F., Graham, C. D., Brazzo, J. A. III, Zurakowski, D., and Fauza, D. O. (2017). Comparisons of human amniotic mesenchymal stem cell viability in FDA-approved collagen-based scaffolds: Implications for engineered diaphragmatic replacement. *J. Pediatr. Surg.* 52, 1010–1013. doi: 10.1016/j.jpedsurg.2017.03.024
- Shrestha, J., Razavi Bazaz, S., Aboulkheyr, Es H, Yaghobian, A. D., Thierry, B., Ebrahimi, W. M., et al. (2020). Lung-on-a-chip: the future of respiratory disease models and pharmacological studies. *Crit. Rev. Biotechnol.* 40, 213–230. doi: 10.1080/07388551.2019.1710458
- Sip, C. G., and Folch, A. (2014). Stable chemical bonding of porous membranes and poly(dimethylsiloxane) devices for long-term cell culture. *Biomicrofluidics* 8:036504. doi: 10.1063/1.4883075
- Strauss, J. F. III (2013). Extracellular matrix dynamics and fetal membrane rupture. *Reprod. Sci.* 20, 140–153. doi: 10.1177/1933719111424454
- Talayev, V. Y., Matveichev, A. V., Lomunova, M. A., Talayeva, M. V., Tsaturov, M. E., Zaichenko, I. Y., et al. (2010). The effect of human placenta cytotrophoblast cells on the maturation and T cell stimulating ability of dendritic cells in vitro. *Clin. Exp. Immunol.* 162, 91–99. doi: 10.1111/j.1365-2249.2010.04149.x
- Taylor, D. L., Gough, A., Schurdak, M. E., Verneti, L., Chennubhotla, C. S., Lefever, D., et al. (2019). Harnessing human microphysiology systems as key experimental models for quantitative systems pharmacology. *Handb. Exp. Pharmacol.* 260, 327–367. doi: 10.1007/164_2019_239
- Truesdell, S. L., George, E. L., and Saunders, M. M. (2020). Cellular considerations for optimizing bone cell culture and remodeling in a lab-on-a-chip platform. *Biotechniques* 68, 263–269. doi: 10.2144/btn-2019-0115
- Uchide, N., Ohyama, K., Bessho, T., Takeichi, M., and Toyoda, H. (2012). Possible roles of proinflammatory and chemoattractive cytokines produced by human fetal membrane cells in the pathology of adverse pregnancy outcomes associated with influenza virus infection. *Mediators Inflamm.* 2012:270670. doi: 10.1155/2012/270670
- Umscheid, C. A., Margolis, D. J., and Grossman, C. E. (2011). Key concepts of clinical trials: a narrative review. *Postgrad. Med.* 123, 194–204. doi: 10.3810/pgm.2011.09.2475
- van den Berg, A., Mummery, C. L., Passier, R., and van der Meer, A. D. (2019). Personalised organs-on-chips: functional testing for precision medicine. *Lab Chip* 19, 198–205. doi: 10.1039/c8lc00827b

- van den Broek, L. J., Bergers, L., Reijnders, C. M. A., and Gibbs, S. (2017). Progress and future perspectives in skin-on-chip development with emphasis on the use of different cell types and technical challenges. *Stem Cell Rev. Rep.* 13, 418–429. doi: 10.1007/s12015-017-9737-1
- van der Helm, M. W., van der Meer, A. D., Eijkel, J. C., van den Berg, A., and Segerink, L. I. (2016). Microfluidic organ-on-chip technology for blood-brain barrier research. *Tissue Barriers* 4:e1142493. doi: 10.1080/21688370.2016.1142493
- van Herendaal, B. J., Oberti, C., and Brosens, I. (1978). Microanatomy of the human amniotic membranes. A light microscopic, transmission, and scanning electron microscopic study. *Am. J. Obstet. Gynecol.* 131, 872–880.
- Vatine, G. D., Barrile, R., Workman, M. J., Sances, S., Barriga, B. K., Rahnama, M., et al. (2019). Human iPSC-derived blood-brain barrier chips enable disease modeling and personalized medicine applications. *Cell Stem Cell* 24:995–1005.e6. doi: 10.1016/j.stem.2019.05.011
- Vickerman, V., Blundo, J., Chung, S., and Kamm, R. (2008). Design, fabrication and implementation of a novel multi-parameter control microfluidic platform for three-dimensional cell culture and real-time imaging. *Lab Chip* 8, 1468–1477. doi: 10.1039/b802395f
- Wan, H., Gu, C., Gan, Y., Wei, X., Zhu, K., Hu, N., et al. (2018). Sensor-free and sensor-based heart-on-a-chip platform: a review of design and applications. *Curr. Pharm. Des.* 24, 5375–5385. doi: 10.2174/1381612825666190207170004
- Wang, J., Khodabukus, A., Rao, L., Vandusen, K., Abutaleb, N., and Bursac, N. (2019). Engineered skeletal muscles for disease modeling and drug discovery. *Biomaterials* 221:119416. doi: 10.1016/j.biomaterials.2019.119416
- Wang, J. D., Douville, N. J., Takayama, S., and ElSayed, M. (2012). Quantitative analysis of molecular absorption into PDMS microfluidic channels. *Ann. Biomed. Eng.* 40, 1862–1873. doi: 10.1007/s10439-012-0562-z
- Weng, L., Lee, G. Y., Liu, J., Kapur, R., Toth, T. L., and Toner, M. (2018). On-chip oocyte denudation from cumulus-oocyte complexes for assisted reproductive therapy. *Lab Chip* 18, 3892–3902. doi: 10.1039/c8lc01075g
- Wilmer, M. J., Ng, C. P., Lanz, H. L., Vulto, P., Suter-Dick, L., and Masereeuw, R. (2016). Kidney-on-a-chip technology for drug-induced nephrotoxicity screening. *Trends Biotechnol.* 34, 156–170. doi: 10.1016/j.tibtech.2015.11.001
- Wu, Q., Fang, T., Lang, H., Chen, M., Shi, P., Pang, X., et al. (2017). Comparison of the proliferation, migration and angiogenic properties of human amniotic epithelial and mesenchymal stem cells and their effects on endothelial cells. *Int. J. Mol. Med.* 39, 918–926. doi: 10.3892/ijmm.2017.2897
- Yin, F., Zhu, Y., Zhang, M., Yu, H., Chen, W., and Qin, J. (2019). A 3D human placenta-on-a-chip model to probe nanoparticle exposure at the placental barrier. *Toxicol. In Vitro* 54, 105–113. doi: 10.1016/j.tiv.2018.08.014
- Zhang, Y. S., Aleman, J., Arneri, A., Bersini, S., Piraino, F., Shin, S. R., et al. (2015). From cardiac tissue engineering to heart-on-a-chip: beating challenges. *Biomed. Mater.* 10:034006. doi: 10.1088/1748-6041/10/3/034006
- Zhang, Y. S., Arneri, A., Bersini, S., Shin, S. R., Zhu, K., Goli-Malekabadi, Z., et al. (2016). Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip. *Biomaterials* 110, 45–59. doi: 10.1016/j.biomaterials.2016.09.003
- Zhao, Y., Rafatian, N., Feric, N. T., Cox, B. J., Aschar-Sobbi, R., Wang, E. Y., et al. (2019). A platform for generation of chamber-specific cardiac tissues and disease modeling. *Cell* 176, 913–927.e18. doi: 10.1016/j.cell.2018.11.042

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Richardson, Kim, Menon and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.